WELCOME TO The PHARMACEUTICAL REPORT
Smith & Nephew Orthopaedics
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
WinHealth | January 04, 2021
Hong Kong WinHealth Pharma Group Co., Ltd. furthermore, Immedica Pharma AB, today declared that they have gone into an understanding under which WinHealth has the restrictive business rights to Ravicti® (Glycerol Phenylbutyrate) for Greater China, South Korea, Singapore, Vietnam , Indonesia, Malaysia , the Philippines and Thailand gets.
Ravicti® is shown for the treatment of urea cycle issue (UCD) in Europe and North America, and as a feature of the reported association, W...
FiercePharma | January 22, 2020
The FDA wants to know what, exactly, is in a drug name. Specifically, can a brand moniker determine how consumers and healthcare providers perceive the drug? So, the agency has launched a study to determine whether names sway opinions about a drug's effectiveness. Drugmakers submit their proposed names to the FDA for approval, but the companies often hire branding agencies to help create a name. The agency’s job is to make up brand names that draw relevant connections but follow FDA gu...
NRx Pharmaceuticals | August 30, 2021
NRx Pharmaceuticals announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment of patients with acute Respiratory Failure due to Critical COVID-19. Previously announced results have focused on survival and recovery from respiratory failure at 60 days, and ZYESAMI's apparent role in preventing rise in the inflammatory cytokine IL-6, known as "Cytokine Storm."
NRx's new analysis shows that patients tr...
Nanoform, Celanese | May 26, 2021
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Celanese Corporation, a global specialty materials company, announced today plans to investigate potential synergies in the field of nanoparticle-enabled drug delivery.
The objective of this research is to determine the utility of combining Nanoform's nanoparticle platform technologies with Celanese's VitalDose® EVA copolymer delivery technology for drug-eluting implants. The objectives are...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE